Vanguard Portfolio Management Reports 5% Passive Stake In Neurocrine Biosciences
Vanguard holds 5,083,540 Neurocrine shares but has sole voting power over only 23,504 of them.
Vanguard Portfolio Management holds 5,083,540 shares of Neurocrine Biosciences, about 5% of the class, according to a passive ownership disclosure (Schedule 13G) filed Friday. Neurocrine is a biopharmaceutical company that develops and sells treatments for neurological, psychiatric, endocrine and immunological disorders.
Big block, little voting power
Vanguard has dispositive power, meaning the authority to decide whether to sell, over the full 5,083,540 shares. Its sole voting power covers only 23,504 shares, and it reports no shared voting power.
The filing ties the position to a September 30, 2026 event date. It counts holdings of two Vanguard affiliates, Vanguard Fiduciary Trust Company and Vanguard Global Advisers, along with Vanguard fund sleeves over which Vanguard Portfolio Management exercises dispositive power.
Vanguard certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Neurocrine.
A drugmaker worth $14.9 billion
Neurocrine shares traded at $147.18 in Friday trading, up about 0.55% from the prior close of $146.38, for a market value of $14.9 billion.
The company sells Ingrezza for tardive dyskinesia and chorea tied to Huntington's disease, and Crenessity for classic congenital adrenal hyperplasia, a rare hormone disorder. Ingrezza net product sales were $2.51 billion for 2025 and Crenessity sales were $301.2 million, according to its annual report.
On Friday the San Diego company also launched two educational resources for physicians on classic congenital adrenal hyperplasia.
Milestone payments from Nxera
Separately, Nxera Pharma said in its quarterly update that it received a US$10 million milestone from Neurocrine tied to progress on an Alzheimer's-related cognitive impairment candidate. It also received US$8.6 million for late-stage progress on an orexin receptor 2 agonist program.
Of the 5,083,540 shares Vanguard reports, only 23,504 carry its sole vote.
Sources
- SCHEDULE 13G — Vanguard Portfolio Management re: Neurocrine Biosciences Inc (NBIX) — SEC EDGAR
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia — Yahoo Finance
- Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026 — Yahoo Finance
- Nxera Pharma Operational Highlights and Consolidated — globenewswire.com
More on Neurocrine Biosciences
- Neurocrine Stock Soars 14%, Adding $2 Billion, After Sales Top $1 Billion And Ingrezza Outlook Rises
- Neurocrine Says FDA Flagged Fluid Retention As A Potential Safety Signal For Its Newly Bought VYKAT XR
- Neurocrine's Product Sales Top $1 Billion In A Quarter For The First Time, And Ingrezza Outlook Rises